Sapien 3 TAVR for younger adults with aortic stenosis in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multi-center, single-arm observational study combines retrospective and prospective data from major cardiac centers in China to examine outcomes after Sapien 3 TAVR in patients aged 50–70 with severe aortic stenosis. The study enrolls both bicuspid and tricuspid valve anatomies and tracks procedural safety, clinical effectiveness, and valve durability over follow-up. Because it is single-arm and real-world, the analysis focuses on rates of complications, hemodynamic performance, and mid-term structural valve outcomes rather than randomized comparison. The study also examines a specific subgroup of patients aged 65–70 who were underrepresented in prior datasets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects must meet ALL of the following inclusion criteria to be eligible for participation:

* 50 years of age or older but ≤70 years old at time of consent.
* Severe AS, defined as follows:

  a) For symptomatic patients: i) Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean gradient ≥40 mm Hg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest b) For asymptomatic patients: i) Very severe AS with an aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec, or mean gradient ≥60 mm Hg by transthoracic echocardiography at rest, OR ii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND a mean gradient ≥40 mm Hg or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND an exercise tolerance test that demonstrates a limited exercise capacity, abnormal BP response, or arrhythmia OR iii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND mean gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND a left ventricular ejection fraction \<50%.
* Tricuspid aortic valve stenosis and type-1 bicuspid aortic valve anatomy confirmed by MDCT.
* The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.
* Adequate iliofemoral access and acceptable level of vessel calcification and tortuosity for safe device implant.
* The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.

Exclusion Criteria:

Subjects are NOT eligible for participation if they meet ANY of the following exclusion criteria:

* Any of the following: a. no calcification; b. challenging calcification based on physician's experience and discretion (Case Review Board would decide whether to exclude challenging calcification cases).
* Aortic valve is a congenital unicuspid valve, congenital Type-0 or Type-2 bicuspid valve, or quadricuspid valve.
* Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm or tortuosity, which prevents transfemoral TAVR.
* Evidence of an acute myocardial infarction ≤ 1 month (30 days), with evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia.
* Need for open heart surgery (including severe aortic regurgitation, mitral regurgitation or stenosis, or tricuspid regurgitation, congenital heart disease, AF, complex coronary artery disease).
* Aortic disease: a. bicuspid aortic valve with an ascending aorta diameter ≥ 45mm b. tricuspid aortic valve with an ascending aorta diameter ≥ 50mm.
* Pre-existing mechanical or bioprosthetic valve in any position.
* Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of the screening visit.
* Emergency interventional/surgical procedures within 30 days of the valve implant procedure.
* Hypertrophic cardiomyopathy with or without obstruction.
* Ventricular dysfunction with LVEF \< 30%.
* Cardiac imaging (echo, CT, and/or MRI) evidence of ventricular mass, thrombus or vegetation.
* Inability (including allergy) to heparin, iodine contrast agent, warfarin or NOAC, aspirin or clopidogrel.
* Stroke or transient ischemic attack (TIA) within 180 days of the valve implant procedure.
* Renal replacement therapy at the time of screening.
* Severe lung disease (FEV1 \< 50% predicted) or currently on home oxygen.
* Estimated life expectancy \< 24 months.
* Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials. Observational studies are not considered exclusionary.

Where it's running

• Department of Cardiovascular Surgery of Xijing Hospital, Air Force Military Medical University
  Xi'an, Shaanxi, China Recruiting
• Shanghai Zhongshan Hospital, Fudan University
  Shanghai, China Recruiting
• West China Hospital, Sichuan University
  Chengdu, Sichuan, China Not yet recruiting
• Fuwai Hospital, Chinese Academy of Medical Sciences
  Beijing, China Not yet recruiting

Study contacts

• Principal investigator: Jian Yang, MD, PhD — Department of Cardiovascular Surgery of Xijing Hospital, Air Force Military Medical University
• Study coordinator: Jian Yang, MD, PhD
• Email: yangjian@fmmu.edu.cn
• Phone: +8613892828016

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vericiguat to slow calcific aortic valve narrowing

  This trial tests whether vericiguat can slow the progression of mild-to-moderate calcific aortic valve stenosis compared with placebo.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07715279

• Surgical implantation of a polymer prosthetic mitral or aortic valve

  This will test a surgically implanted polymer heart valve to see if it is safe and works well for adults who need mitral or aortic valve replacement.

  Recruiting Mitrassist Lifesciences Limited Co., Ltd. · Shanghai, Shanghai Municipality · NCT07097740

• Comparing two ways to stabilize the bicuspid aortic valve during repair

  This trial will test whether an internal HAART 200 annuloplasty device or a double external ring annuloplasty gives better repair results for adults with asymmetric bicuspid aortic valves and severe aortic regurgitation who need valve surgery.

  Recruiting at 2 sites University Hospital Augsburg · Augsburg, Bavaria and 3 other locations · NCT06869954

• Transfemoral VitaFlow Liberty treatment for pure aortic regurgitation

  This trial will test whether replacing the aortic valve through the leg with the VitaFlow Liberty valve plus usual medical care helps people aged 60 and older with moderate-to-severe or worse isolated aortic regurgitation.

  Recruiting at 4 sites Phase 4 Ruijin Hospital · Shanghai, Shanghai Municipality and 3 other locations · NCT06818084

• Observing the progression of bicuspid aortic valve in Chinese patients

  This study looks at how bicuspid aortic valve affects young Chinese patients over time to better understand the condition and improve treatment options.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06802016

• Evaluating the LIRA method for sizing in patients with bicuspid aortic valves

  This study is testing a new sizing method for heart valve replacement in adults with a specific type of heart valve problem to see if it can make the procedure safer and more effective.

  Recruiting at 5 sites IRCCS San Raffaele · Brescia, Italy and 4 other locations · NCT06657911

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.